The drug combination of SB202190 and SP600125 significantly inhibit the growth and metastasis of olaparib-resistant ovarian cancer cell.
CONCLUSION: Our data suggested that aberrant over-expression of P38 and JNK is causally linked to olaparib resistance in ovarian cancer. Combination of P38 and JUN inhibitors demonstrated significantly anti-tumor activity both in vitro and in vivo. Our study highlighted the potential therapeutic value of Mitogen-Activated Protein Kinase (MAPK) inhibitors in olaparib-resistant human ovarian cancer.
PMID: 30003858 [PubMed - as supplied by publisher]
Source: Current Pharmaceutical Biotechnology - Category: Biotechnology Authors: Chen X, Chen Y, Lin X, Su S, Hou X, Zhang Q, Tian Y Tags: Curr Pharm Biotechnol Source Type: research
More News: Biotechnology | Cancer | Cancer & Oncology | Epithelial Cancer | Ovarian Cancer | Ovaries | Study